BioCatalystWatch
MRKWorkspace / MRK / OverviewCompany library
Price
Market cap
Next catalystRemaining ATLAS-UC readout near term, within retained H2 2026 guidanceTulisokibart — ATLAS-UC · Phase 3 dataCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

Tulisokibart — ATLAS-UC

TL1A

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Wnt pathway agonist

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

HIF-2α × multiple receptor tyrosine kinases

PreINDP1P2P3FilingApproved
Upcoming / outlook

VEGFR1 (FLT1) × VEGFR2 (KDR) × VEGFR3 (FLT4) × FGFR1-4 × PDGFRα × KIT × RET

PreINDP1P2P3FilingApproved
Upcoming / outlook

KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph)

PD-1

Approved

PreINDP1P2P3FilingApproved
KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph)

PD-1

Approved

PreINDP1P2P3FilingApproved
Upcoming / outlook

Influenza neuraminidase

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

RSV F protein

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

HIV-1 reverse transcriptase

PreINDP1P2P3FilingApproved
Upcoming / outlook

Activin A × TGF-β Superfamily Ligands

PreINDP1P2FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Tulisokibart — ATLAS-UC

TL1A

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Activin A × TGF-β Superfamily Ligands

PreINDP1P2FilingApproved
Upcoming / outlook

KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph)

PD-1

Approved

PreINDP1P2P3FilingApproved
Upcoming / outlook

Wnt pathway agonist

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

Partner / License out

PreINDP1P2P3FilingApproved

Approved / commercial

KEYTRUDA plus LENVIMA

PD-1

Approved

PreINDP1P2P3FilingApproved

PCSK9

PreINDP1P2P3FilingApproved
Upcoming / outlook

PD-1

Approved

PreINDP1P2P3FilingApproved

PD-1

Approved

PreINDP1P2P3FilingApproved
Upcoming / outlook

PD-1

Approved

PreINDP1P2P3FilingApproved
Keytruda

PD-1

Approved

PreINDP1P2P3FilingApproved
Keytruda

PD-1

Approved

PreINDP1P2P3FilingApproved
Keytruda

PD-1

Approved

PreINDP1P2P3FilingApproved
Keytruda

PD-1

Approved

PreINDP1P2P3FilingApproved

History / paused

BTK

PreINDP1P2P3FilingApproved

BTK

PreINDP1P2P3FilingApproved

PCSK9

PreINDP1P2P3FilingApproved

PCSK9

PreINDP1P2P3FilingApproved

CDH6

PreINDP1P2P3FilingApproved
Lagevrio

Viral RNA Polymerase

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

MRK PR & News

PR & News

MRK SEC archive